156 related articles for article (PubMed ID: 17266043)
1. Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin.
Wang HW; Lin CP; Chiu JH; Chow KC; Kuo KT; Lin CS; Wang LS
Int J Cancer; 2007 May; 120(9):2019-27. PubMed ID: 17266043
[TBL] [Abstract][Full Text] [Related]
2. Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily.
Steckelbroeck S; Oyesanmi B; Jin Y; Lee SH; Kloosterboer HJ; Penning TM
J Pharmacol Exp Ther; 2006 Mar; 316(3):1300-9. PubMed ID: 16339391
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
[TBL] [Abstract][Full Text] [Related]
4. AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer.
Zhu H; Chang LL; Yan FJ; Hu Y; Zeng CM; Zhou TY; Yuan T; Ying MD; Cao J; He QJ; Yang B
Theranostics; 2018; 8(3):676-692. PubMed ID: 29344298
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis.
Selga E; Noé V; Ciudad CJ
Biochem Pharmacol; 2008 Jan; 75(2):414-26. PubMed ID: 17945194
[TBL] [Abstract][Full Text] [Related]
6. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling.
Ji Q; Aoyama C; Nien YD; Liu PI; Chen PK; Chang L; Stanczyk FZ; Stolz A
Cancer Res; 2004 Oct; 64(20):7610-7. PubMed ID: 15492289
[TBL] [Abstract][Full Text] [Related]
7. Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Shiiba M; Yamagami H; Yamamoto A; Minakawa Y; Okamoto A; Kasamatsu A; Sakamoto Y; Uzawa K; Takiguchi Y; Tanzawa H
Oncol Rep; 2017 Apr; 37(4):2025-2032. PubMed ID: 28259989
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification.
Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT
Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386
[TBL] [Abstract][Full Text] [Related]
9. The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoate induced esophageal squamous cell carcinoma cell death.
Li W; Hou G; Zhou D; Lou X; Xu Y; Liu S; Zhao X
Oncotarget; 2016 Apr; 7(16):21542-55. PubMed ID: 26934124
[TBL] [Abstract][Full Text] [Related]
10. AKR1C enzymes sustain therapy resistance in paediatric T-ALL.
Bortolozzi R; Bresolin S; Rampazzo E; Paganin M; Maule F; Mariotto E; Boso D; Minuzzo S; Agnusdei V; Viola G; Te Kronnie G; Cazzaniga G; Basso G; Persano L
Br J Cancer; 2018 Apr; 118(7):985-994. PubMed ID: 29515258
[TBL] [Abstract][Full Text] [Related]
11. Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Matsumoto R; Tsuda M; Yoshida K; Tanino M; Kimura T; Nishihara H; Abe T; Shinohara N; Nonomura K; Tanaka S
Sci Rep; 2016 Oct; 6():34625. PubMed ID: 27698389
[TBL] [Abstract][Full Text] [Related]
12. Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer.
Wenners A; Hartmann F; Jochens A; Roemer AM; Alkatout I; Klapper W; van Mackelenbergh M; Mundhenke C; Jonat W; Bauer M
Int J Clin Oncol; 2016 Jun; 21(3):548-56. PubMed ID: 26573806
[TBL] [Abstract][Full Text] [Related]
13. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
Chang WM; Chang YC; Yang YC; Lin SK; Chang PM; Hsiao M
J Exp Clin Cancer Res; 2019 Jun; 38(1):245. PubMed ID: 31182137
[TBL] [Abstract][Full Text] [Related]
14. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway.
Xu X; Zhang Y; Li W; Miao H; Zhang H; Zhou Y; Li Z; You Q; Zhao L; Guo Q
Biochem Pharmacol; 2014 Nov; 92(2):220-34. PubMed ID: 25264278
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of aldo-keto reductases AKR1C1-AKR1C4.
Brožič P; Turk S; Rižner TL; Gobec S
Curr Med Chem; 2011; 18(17):2554-65. PubMed ID: 21568892
[TBL] [Abstract][Full Text] [Related]
16. Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung.
Hung JJ; Chow KC; Wang HW; Wang LS
Anticancer Res; 2006; 26(4B):2949-55. PubMed ID: 16886619
[TBL] [Abstract][Full Text] [Related]
17. Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species.
He F; Wang Q; Zheng XL; Yan JQ; Yang L; Sun H; Hu LN; Lin Y; Wang X
Oncol Rep; 2012 Aug; 28(2):601-5. PubMed ID: 22665077
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1).
El-Kabbani O; Dhagat U; Hara A
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):105-11. PubMed ID: 21050889
[TBL] [Abstract][Full Text] [Related]
19. Scutellaria Flavonoids Effectively Inhibit the Malignant Phenotypes of Non-small Cell Lung Cancer in an Id1-dependent Manner.
Zhao Z; Liu B; Sun J; Lu L; Liu L; Qiu J; Li Q; Yan C; Jiang S; Mohammadtursun N; Ma W; Li M; Dong J; Gong W
Int J Biol Sci; 2019; 15(7):1500-1513. PubMed ID: 31337979
[TBL] [Abstract][Full Text] [Related]
20. Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors.
Chu X; He S; Liu Y; Liu Y; Feng F; Guo Q; Zhao L; Sun H
Chem Biol Interact; 2022 Jan; 351():109746. PubMed ID: 34780792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
